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The viral enzyme integrase (IN) is essential for the replication of human 
immunodeficiency virus type 1 (HIV-1) and represents an important target for the 
development of new antiretroviral drugs. In this PhD project, we focused on the                  
N-terminal domain of integrase (NTD) for the development and synthesis of a library 
of overlapping peptide sequences, with specific length and specific offset covering 
the entire native protein sequence NTD IN 1-50. The most potent fragment, 
VVAKEIVAH (peptide 18), inhibits the HIV-1 IN activity with an IC50 value of                     
4.5 µM. Amino acid substitution analysis on this peptide revealed essential residues 
for activity and allowed us to identify two nonapeptides (peptides 24 and 25), that 
show a potency of inhibition similar to peptide 18. Interestingly, peptide 18 does not 
interfere with the dynamic interplay between IN subunits, while peptides 24 and 25 
modulate these interactions in different manners. In fact, peptide 24 inhibits the                      
IN-IN dimerization, while peptide 25 promotes IN multimerization, with IC50 values 
of 32 and 4.8 µM, respectively. In addition, peptide 25 has shown to have selective 
anti-infective cell activity for HIV-1. Moreover, the NMR analysis showed an alpha 
helix conformation of peptide 25, which could be essential for the interaction with IN. 
These results indicated peptide 25 as a hit for further development of new 
chemotherapeutic agents against HIV-1. In addition, we observed that the peptide 5, 
EKYHSNWRAM, conveniently conjugated with the cell-penetrating fragment TAT, 
inhibits replication of HIV-1 and HIV-2 in infected MT-4 cells.  
 
Keywords: HIV-1, integrase, N-terminal domain, peptides, inhibitors. 
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1. Acquired immune deficiency syndrome (AIDS) 
 
1.1 Global distribution of HIV-1 infection  
 
Acquired immune deficiency syndrome (AIDS), is induced by HIV 
infection and consists in a profoundly damage of immune system.  
Following the discovery of the HIV as the causative agent of AIDS, 
many advances were made in a short period of time, including the 
understanding of the modes of transmission; the sequencing of the HIV-
1 genome;
1
 elucidation of the main cell targets, CD4 T cells and 
macrophages;
2
 the genomic heterogeneity of HIV with the innumerable 
micro variants within a single patient;
3
 identification of a SIV-monkey 
model to study and monitoring the epidemic events.
4
 Human 
immunodeficiency virus (HIV), is a retrovirus known for immune 
system degradation, transmitted by direct contact with infected blood, 
sexual contact or by direct transmission of mother to child. The HIV 
virus has remained a predominant health care concern for the past 30 
years.
5
 Around 35 million people have died from AIDS-related illnesses 
since the first cases of HIV were reported, and, overall, 78 million have 
been infected with HIV, according to UNAIDS, the Joint United Nations 
Programme on HIV/AIDS. Thanks to a dramatic scale-up of 
antiretroviral treatment, AIDS-related deaths have fallen by 45% to1.1 
million in 2015 from a peak of 2 million in 2005. Globally, 36.7 million 
people were living with HIV in 2015, the majority in poor and middle-
income countries. As of June 2016, around 18.2 million were receiving 
antiretroviral therapy, up from 15.8 million at the same time last year, 
and 7.5 million in 2010 (figure 1.1). 





Figure 1.1 Population of people living with HIV in 2015. 
Adapted from: http://chartsbin.com/view/11852. 
 
Last year, around 2.1 million people became newly infected with HIV. 
While the number of adults acquiring the virus is not falling, huge 
advances have been made in tackling mother to child transmissions. In 
the past five years, new infections among children halved 150.000 in 
2015, down from 290.000 in 2010. UNAIDs warns that young women 
are particularly at risk of infection. In sub Saharan Africa, adolescent 
girls face a triple threat: a high risk of HIV infection, low rates of HIV 
testing and difficulty sticking with HIV treatment. The first approved 
therapy involved the use of multiple drugs (HAART, Highly Active 
Anti-Retroviral Therapy),
6
 which transform the HIV infection from 
lethal to chronic. Despite this, due to drug resistance that are highlighted 
below, the treatment regimen has not allowed the complete eradication 
of the disease itself. The treatment only reduced the number of new 
infections and subsequent deaths, but despite these promising advances, 
HIV infection remains a looming problem on global health and an 
important goal for scientific research.  
 





1.2 HIV Genome  
 
The HIV virus belongs to the retroviruses family and is a member of the 
genus of lentiviruses, which indicates a long incubation period. The 
essential genes for replication and then for virus activity are: gag, pol, 
and env. The gag gene encodes the nucleocapsid protein; the pol gene 
encodes the enzyme reverse transcriptase, protease and integrase; 
Finally, env encodes for the proteins of the pericapside.
7,8
 The HIV 
genome also contains, at the sides of the env gene, six more genes that 
code for regulatory proteins and accessory: tat (transactivation of 
Transcription), rev (Regulatory of Virus), vpu (Viral Protein U), nef 
(Negative Factor) , vif (viral infectivity factor) and vpr (Viral Protein R), 
involved in different steps in regulation and HIV pathogenesis. A 
conceptual representation of the virus architecture is represented in 
figure 1.2. 
 









1.2.1 Replicative cycle of HIV-1 
 
Replicative cycle of the virus can be divided into different stages: 
penetration of the virus within the host cell, reverse transcription of the 
viral genome and introduction into the host cell genome by the integrase 
enzyme, the production of second messengers and, finally, assembly of 
new infectious virions during the late phase. The infection begins when 
the envelope (Env) glycoprotein gp120 binds the receptor CD4 and the 
co-receptor CC-chemokine receptor 5 (CCR5) (step 1), leading to fusion 
of the viral and cellular membranes and entry of the viral particle into 
the cell (step 2). The role of the CD4 receptor in HIV cell entry was 
identified shortly after the isolation of HIV.
9
 The conformational 
changes in the gp120 protein leads to exposing an epitope which allows 
binding to a co-receptor, such as the chemokine receptors CCR5 or 
CXCR4, which are the most co-receptors used by HIV in vivo. The 
importance of this co-receptor binding was empathized by the 
compromised HIV-1 infectivity in the individuals harbouring mutant 
CCR5 proteins.
10
 Partial core shell uncoating (step 3) facilitates reverse 
transcription (step 4). This step is catalyzed by the viral enzyme reverse 
transcriptase (RT), which transcribes the viral single-stranded RNA 
genome which is converted into double-stranded DNA (dsDNA). 
Together with viral and host proteins the dsDNA forms the pre-
integration complex (PIC), which is guided to the nuclear pore. This is 
an essential step in the HIV replication cycle of HIV because it prepares 
the viral genome for the subsequent integration into the host 
chromosome. Following of displacement into the cell nucleus (step 5), 
PIC-associated viral integrase forms the integrated provirus (step 6).  
Proviral transcription (step 7), mediated by host RNA polymerase II 
(RNA Pol II) and positive transcription elongation factor b (P-TEFb),  






yields viral mRNAs of different sizes, the larger of which requires 
energy-dependent export to leave the nucleus via host protein CRM1 
(step 8). mRNAs is used as templates for protein production (step 9) and 
genome-length RNA is incorporated into viral particles with protein 
components (step 10). Viral-particle budding (step 11) and release (step 
12) from the cell is mediated by ESCRT (endosome sorting complex 
required for transport) complexes. Each step in the HIV-1 life cycle is a 
potential target for antiviral intervention;
6
 The sites of action of clinical 
inhibitors and cellular restriction factors are indicated in the figure 1.3.  
 
 
Figure 1.3  Schematic overview of the HIV-1 replication cycle. 
Adapted from: Engelman A and Cherepanov P. The structural biology of HIV-













1.3 Antiretroviral Drugs 
 
The significant advancement in the understanding of HIV replication 
and its pathogenesis has helped in the identification of various 
pharmacological targets. The first anti-HIV agent to be licensed for 
clinical use was Zidovudine (AZT), in 1987. Since then, several anti-
HIV compounds have been approved for the treatment of AIDS by the 
FDA and EMEA (European Medicine Agency) for treating HIV 
infections.
11
 These compounds fall within different categories depending 
on the target within the HIV replicative cycle they interact with.  
 
1.3.1 The Entry and Fusion Inhibitors 
 
These inhibitors intercept the viral replication at the entry of the viral 
core into the cytosol of the host cell. The group of entry inhibitors can be 
subdivided into classes of agents that act at different stages of entry: 
attachment and CD4 binding, co-receptor binding, and fusion. In the 
recent years, important progress has been made in understanding the 
HIV-1 entry process in which the viral and cellular membranes are 
fused, resulting in the subsequent delivery of the viral genome into the 
host cell. These studies have led to the formulation of new approaches 
for therapeutic intervention. One of the first and clinically most 
advanced drug emerged from this effort is the fusion inhibitor T20. T20 
acts by freezing a transient structural intermediate of the HIV-1 fusion 
process, thus blocking an essential step in viral entry. With phase III 
clinical trials already well underway, the success of T20 indicates that 
targeting the viral entry process will soon be an important component of 









the ENF binding site on gp41 (direct resistance) or confer resistance 
indirectly via mutations in other regions of gp41 and even in gp120.
12  
Currently, only antagonists that block CCR5 binding (Maraviroc) and 
fusion (Enfuvirtide) have been approved by the FDA for treatment of 
HIV infected patients, although strategies to inhibit other aspects of HIV 
entry are under development.
13
 In addition to Maraviroc, other CCR5 




1.3.2 The Reverse Transcriptase (RT) Inhibitors 
 
The Reverse Transcriptase (RT) inhibitors interfere with the generation 
of a DNA copy of the viral genome. RT functions as a heterodimer and 
catalyzes the conversion of the single-stranded genomic RNA into 
double-stranded DNA (with duplicated long terminal repeats), which is 
integrated into cellular DNA by the viral integrase.
15
 There are two 
classes of RT inhibitors, that exhibit different mechanism of action. First 
of them is the group of nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs). These are nucleoside and nucleotide analogues that 
are incorporated by the viral RT into the newly synthesized DNA strand. 
They are inactive in their parent forms and require successive 
phosphorylation steps by host cell kinases and phosphotransferases to 
form deoxynucleoside triphosphate (dNTP) analogs responsible of viral 
inhibition. In their respective triphosphate (TP) forms, NRTIs compete 
with their corresponding endogenous dNTPs for incorporation by HIV 
RT. Once incorporated, they assist as terminators chain of viral RT, thus, 
acting early in the viral replication cycle by inhibiting a critical step of 











The currently approved NRTIs are Zidovudine, Lamivudine, 
Didanosine, Zalcitabine, Stavudine, Abacavir, and Emtricitabine.  
The second group of RT inhibitors is the Non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). They are small molecules that carry 
out the inhibition of RT by binding to a hydrophobic pocket in the 
proximity of the active site of the enzyme. After the inhibitor is bound, it 
impairs the flexibility of the RT resulting in its inability to synthesize 
DNA. Mutations may induce resistance to NNRTIs resulting in reduced 
affinity of the inhibitor with the protein. Usually, a single mutation 
selected by one NNRTI is sufficient to confer complete resistance to all 




1.3.3 The Protease Inhibitors (PIs) 
 
Protease Inhibitors (PIs) interfere with the process of forming new 
infectious viral particles. The viral protease is involved in virion 
maturation. Protease targets the amino acid sequences in the gag and 
gag–pol polyproteins, which must be cleaved before nascent viral 
particles (virions) can mature. Cleavage of the gag polyprotein produces 
three large proteins (p24, p17, and p7) that contribute to the structure of 
the virion and to RNA packaging, and three small proteins (p6, p2, and 
p1) of uncertain function. PIs are small molecules that bind to the active 
site of the protease and compete with its natural substrates. PIs contain a 
synthetic analogue of the amino acid sequence of the gag–pol 
polyprotein that is cleaved by the protease. PIs prevent cleavage of gag 
and gag–pol protein precursors in acutely and chronically infected cells, 












The resistance of HIV against PIs can be achieved by two mechanisms. 
The first one involves the exchange of amino acids in the protease such 
that the affinity to the inhibitor is decreased while the natural substrates 
can be bound efficiently as opposed to the synthetic analogues.
18
 
Modifications of the affinity to the natural substrate alter also the 
efficiency of the protease. Thus, the second mechanism introduces 
compensatory mutations aiming at re-establishing the efficiency of the 
enzyme while maintaining resistance against the inhibitor. These 
mutations can occur both in the protease or in its substrate, at cleavage 
sites.
19
 The four approved HIV-protease inhibitors are based on amino 
acid sequences: Indinavir, Nelfinavir, Ritonavir and Saquinavir.  
 
1.4 Highly Active Antiretroviral Therapy (HAART) and resistance 
effect to drugs 
 
The HIV virus develops resistance against individual drugs and 
inhibitors. This problem required a new pharmaceutical strategy. An 
approach of combination therapy, which involved combining several 
antiretroviral compounds, was developed. This approach benefited the 
most from the development of drugs in NNRTIs and PI classes. 
Combination therapy can block the resistance effect more effectively for 
two reasons; first, multiple mechanisms are required for resistance to 
occur to all drugs in the regimen and second; multiple drugs suppress 
viral replication more effectively than single agents. This marked the 
beginning of the era of highly active antiretroviral therapy (HAART) in 
1995. HAART combines a minimum of three drugs from at least two 
different drug classes targeting distinct proteins.
17
 A typical HAART 











Combinations of antiretrovirals create multiple barriers to the HIV 
replication process. This helps to keep the number of offspring low and 
reduce the possibility of a superior mutation. 
In 2006, it was reported that the number of HIV related deaths declined 
as compared to the pre-HAART. Consequently, multidrug regimens are 
necessary for successful treatment. Since each HAART agent has its 
own unique adverse effect profile, selecting a regimen with a proper 
profile may be difficult. For example, certain PIs produce adverse 
metabolic effects that may increase the risk of developing cardiovascular 
disease. On the other hand, NNRTI-based therapies may result a 
different side effect profile. Once this therapy is initiated, it should never 
be stopped.  
In 2006, FDA approved the combinations of antiretrovirals (for example, 
Atripla). These are multiple antiretroviral drugs combined into a single 
pill, helping to increase adherence and thus reducing potential 
development of viral resistance to the drugs. This may result in longer 
term effectiveness of the regimen. They may combine different classes 
of antiretrovirals or contain only a single class. Another milestone in 
HAART was the discovery that the protease inhibitor ritonavir interferes 
with the liver enzyme cytochrome P450.
21
 
This enzyme is involved in the metabolic processing of most protease 
inhibitors. Thus, the use of a small dose of ritonavir inhibits the liver 
enzyme, and helps to maintain optimal levels of other protease inhibitors 
in the patient‟s circle for a longer period of time. The boosting of 
protease inhibitors with ritonavir is standard as of 2001 following the 
introduction of Kaletra (LPV+RTV) and is usually denoted by PI/r. 
Despite the increasing concerns regarding antiretroviral resistance, the 
death rate among HIV-infected people continued to decline.
22
 





HAART suffers from certain limitations, despite of its success. HAART 
therapy is highly effective in delaying the onset of AIDS but its clinical 
utility is limited by viral resistance, non-adherence to therapy, and drug 
toxicity. Thus, the development of new inhibitors, targeting a distinct 
step in the retroviral life cycle, remains essential to reduce side effects 
and selection of drug-resistant viruses. In this context, integration of the 
proviral DNA into the host cell genome, a process carried out by a 
specific viral enzyme, integrase, has been recently recognised as site for 
therapeutic intervention. Development of new chemical entities able to 
interrupt this process, would allow to identify key biochemical sites of 
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2.1 Integrase and integration: biochemical activities of HIV-1 
integrase 
 
2.1.1 Integrase protein 
 
As mentioned above, the human immunodeficiency virus (HIV) that 
causes acquired immunodeficiency syndrome (AIDS), belongs to the 
family of Retroviridae, genus Lentivirinae. Lentiviruses represent a kind 
of slow viruses with a long incubation period (months, even years) and a 
propensity to induce a wide range of diseases in different animal species. 
According to the recent classification of the International Committee on 
Taxonomy of Viruses (ICTV), the genus Lentivirus consists of nine 
species, seven lentivirus animal and two human lentivirus. At the same 
time there exist different species of integrase. For example, PFV IN is 
significantly longer, comprises 392 residues and ASV IN is decoded into 
323 amino acids and is only in post-translational phase modified 
polypeptide comprising 286 residues, which is the active form.
1
  
Although the enzyme encoded by avian sarcoma virus (ASV) has been 
studied long before,  it is clear that is more interesting to study HIV IN.
2
 
The integrase of HIV-1 is structurally characterized by a single 
polypeptide chain consisting of 290 amino acid residues and consists of 
three clearly identifiable domains and inter-domain linker.
3 
 





Figure 2.1 Amino acid sequence alignment of retroviral integrase. 
Adapted from: Jaskolski M, Alexandratos JN, Bujacz G and Wlodawer A. 
Piecing together the structure of retroviral integrase, an important target in 
AIDS therapy. FEBS J. 2009; 276(11): 2926–2946. 
 
As shown in the figure 2.1, the N-terminal domain (NTD) of HIV-1 IN 
contains the residues from 1 to 46, followed by a linker consisting of 
from 47-55 residues. The catalytic domain (CCD) contains 56-202 
residues, and is followed by a linker sequence which comprises the 
amino acids from 203 to 219. Finally, the C-terminal domain (CTD) 
contains 220-288 residues. The number of domain residues of HIV-2 
and SIV enzymes is approximately equal, which differs for ASV IN.  
 
 




For the PFV IN, it is possible that there is an additional domain consists 
of approximately 50 residues preceding the NTD domain.  
Analyzing for individual domains the ratio of the percentage 
identity/similarity are obtained the following data: for NTD 55/76% 
comparing HIV-1 IN to SIV, 26/46% comparing ASV IN; for the CCD 
are respectively 61/77% and 27/46% and for the CTD are 53/68% and 
14/25% respectively. It is know that the lower sequence conservation is 
for the C-terminal domain.
4
 
However, it should be emphasized, that the domains are characterized by 
a highly conserved sequence in all retroviral integrase: 
• CCD has three highly conserved amino acid residues (DDE motif) 
• NTD sequence corresponds to HHCC residues. 
 
2.1.2 The role of integrase in HIV-1 replication 
 
Integrase (IN) is a key enzyme for the integration of the HIV-1 genome 
into the host cell chromosome and, therefore, a very promising target for 
anti-AIDS drug design. IN performs two essential catalytic reactions.
5
  
Following reverse transcription, the viral cDNA is primed for integration 
in the cytoplasm by integrase-mediated trimming of the 3′-ends of the 
viral DNA (figure 2.2). This step is referred to as 3′-Processing. It 
requires both fully functional integrase and the integrity of the last 10–
20 base pairs at both ends of the viral cDNA. 3′-processing consists of 
the endonucleolytic cleavage of the 3′-ends of the viral DNA.  
This cleavage occurs immediately 3′ to a conserved CA dinucleotide 
motif. Alterations of this sequence prevent integrase from catalysing 3′-
processing. This reaction generates CA-3′-hydroxyl DNA ends, which 








Following 3′-processing, integrase remains bound to the viral cDNA as a 
multimeric complex that bridges both ends of the viral DNA within the 
PIC.  
The PIC contains both viral and cellular proteins in addition to the 
integrase–DNA complexes. The viral proteins reverse transcriptase 
(RT), matrix (Ma), nucleocapsid (Nc) and Vpr can contribute to the 
transport of PICs through the nuclear envelope. Some cellular proteins, 
packaged within PICs, can bind to integrase and stimulate the enzymatic 
activities of integrase. These proteins include interactor 1 (INI1)16 (the 
first integrase-binding protein discovered), lens epithelium derived 
growth factor (LEDGF, also known as p75);
6
 embryonic ectoderm-
development protein 18 and heat shock protein 60 (HSP60).
7
 
Promyelocytic leukaemia protein (PML) also co-localizes and              
co-migrates with PICs20. Two cellular proteins, high-mobility group 
protein A1 (HMGA1, also known as HMG1(Y)) and barrier to auto-
integration factor (BAF), regulate integration by binding to DNA 
directly. HMGA1 stimulates integrase activity;
8,9 
 BAF stimulates 
intermolecular integration and suppresses auto-integration. By contrast 
to other lentiviruses, such as the oncoretroviruses murine Moloney virus 
and Rous sarcoma virus, which require mitotic nuclear-envelope 
breakdown to access the chromosomes of infected cells, HIV-1 PICs are 
able to cross the nuclear envelope. The karyophilic property of the PICs 
enables HIV to replicate in not proliferative cells, such as 
macrophages.
10
 Once in the nucleus, integrase catalyzes the insertion of 
the viral cDNA ends into host chromosomes. This Strand Transfer 
reaction consists of the ligation of the viral 3′-OH DNA ends (generated 
by 3′-processing) to the 5′-DNA phosphate of a host chromosome.  
 
 




Integrase can also catalyse the reverse reaction, referred to as 
Disintegration.
11
 Physiological integration requires the concerted joining 
of both ends of the viral cDNA on opposite DNA strands of the target 
(acceptor DNA) host chromosome with a canonical fivebase-pair 
stagger. The five-base stagger indicates that each viral cDNA end 
attacks the chromosomal DNA across its major groove. Completion of 
integration requires ligation of the 5′-end of the viral DNA. This last step 
of integration can only take place after trimming of the last two 
nucleotides at the proviral DNA 5′-ends and extension (gap filling) from 
the 3′-OH remodelling, and transcription complexes, such as those 
bound to integrase in the PICs (and described above), are implicated in 
the selection of the HIV integration sites within transcribing genes. The 












2.1.3 HIV integrase structure and functional domains  
 
Integrase is generated during virus maturation by cleavage of the Pol 
polyprotein by HIV protease. HIV integrase is a 32-kDa protein 
comprising three structural domains: the N-terminal domain (NTD), the 
catalytic core domain (CCD) and the C-terminal domain (CTD) (figure 
2.3). The atomic structure of each of these domains has been determined 




Figure 2.3 Functional domain of integrase.  
Adapted from: Kessl JJ, McKee CJ, Eidahl JO, Shkriabai N, Katz A and 
Kvaratskhelia M. HIV-1 Integrase-DNA Recognition Mechanisms. Viruses. 
2009; 1(3), 713-736.  
 
The figure 2.4 shows the structures of the CCD in association with the 
CTD,
12
 and of the NTD with the CCD.
13
 CCD, which encompasses 
residues 50–212, forms a dimer in all the structures examined. It is, 
structurally, remarkably similar to other retroviral integrases (MLV and 
avian sarcoma virus (ASV)), to the Tn5, to RNase H, to the Holiday 








the RNase associated with Dicer in RNA interference. This family of 
DNA processing enzymes (polynucleotide transferases) contains a 
canonical three amino acid, which formed in HIV-1 integrase the 
catalytic triad D64, D116 and E152. These residues are highly conserved 
in all integrases and retrotransposases (DDE motif).
15
 Mutation of any of 
these three acidic residues abolishes integrase‟s enzymatic activities and 
viral replication. The two D64 and D116 residues form a coordination 





Because a second metal has been observed in an ASV integrase crystal 
structure,
16
 and because of the two-metal structure for polynucleotide 
transferases,
17





can be coordinated between D116 and E152 once HIV-1 integrase binds 
its DNA substrate(s).
18
 It is therefore likely that the metal(s) 
coordinate(s) integrase and the phosphodiester backbone of the DNA 
substrate(s) during the 3′-processing and strand-transfer steps. In most 
structures, the CCD contains a short disordered loop (encompassing 
residues 141–150), the structure of which can be stabilized by DNA. 
Although the CCD contains the enzyme catalytic site(s), in the absence 
of the NTD and CTD it can only catalyze the disintegration reaction the 
reverse of the strand-transfer reaction in vitro.
19
 Disintegration is the 
only reaction catalyzed by the isolated CCD. To catalyze 3′-processing 
and strand transfer, the CCD needs both the NTD and CTD in a dimeric 
complex.
20 The NTD encompasses residues 1–50 and contains an HHCC 
motif that is common to all retroviral integrases. Binding of one Zn
2+
 
atom to the HHCC motif stabilizes the folding of the NTD domain and is 
required for integrase activity. Single mutations of any of these four 
residues reduce integrase enzymatic activity.
21
 The NTD dimer interface 
is different in the crystal structures and the solution NMR structure (not  
 




shown), which is indicative of multiple arrangements of the integrase 
multimers. The NTD is the preferential binding region for two cellular 
transcription factors in the PICs, INI1 and LEDGF/p75. The CTD, 
which encompasses residues 212–288, has an overall SH3 fold. It binds 
DNA nonspecifically and is required for integrase 3′-processing and 
strand-transfer activities. The CTD binds the cellular embryonic 
ectoderm development protein as well as RT, and this interaction seems 
to be required for reverse transcription. The figure 2.4 shows the 
structures of the CCD both with the NTD and the CTD. Together these 
two structures indicate the possibility that the NTD is positioned 
between the CCD and CTD, next to the extended α-helix joining the 
CCD and the CTD. The solution NMR dimer interfaces for the NTD and 
the CTD, which are different from those observed in the crystallographic 
structure  might be used in higher-order complexes (tetramers and/or 








Figure 2.4 The structures of the CCD in association with the CTD, and of the 
NTD with the CCD. a and b | Side views showing the catalytic acidic triad in 
red (the canonical DDE motif consisting of residues D64, D116, E152; BOX 1, 
figure part a) in the catalytic core domain (CCD) of integrase. The two 
subunits of the dimer are shown in yellow and green. c and d | Front views of 
the same structures (after 90° anticlockwise rotation of panels a and b, 
respectively). a and c | Structure of the CCD–carboxy-terminal domain (CTD) 
dimer; (PDB codes: 1EXQ & 1EX4). b and d | Structure of the amino-terminal 
domain (NTD)–CCD (PDB code: 1K6Y). Combining the structures (a with b; c 
with d) indicates the positioning of each NTD into the cavity between the CCD 
and CTD in the full-size integrase dimer. The functional structure of integrase 
is probably tetrameric, and would therefore involve another dimer interface 
(unknown, and therefore not represented here).  
Adapted from: Pommier Y, Johnson AA and Marchand C. Integrase inhibitors 
to treat HIV/Aids. Nature Reviews Drug Discovery. 2005; 4, 236-248. 
  
2.1.4 IN interactions with host cell proteins 
 
Purified IN proteins catalyzes 3′ processing and DNA strand transfer 
activities in vitro,
22,23
 indeed, the results obtained by numerous studies 
indicate that cell proteins play important roles, during virus infection. In 
particular, a crucial role for the IN-interacting protein lens epithelium- 
 




derived growth factor (LEDGF)/p75 in HIV-1 replication and integration 
has highlighted.
24
 However, the function of LEDGF/p75 in viral 
replication is unknown. 
The LEDGF/p75 belongs to the hepatoma-derived growth factor 
(HDGF) related protein (HRP) family, which is defined by the amino 
acid sequence conservation of an N-terminal Pro-Trp-Trp-Pro (PWWP) 
domain (figure 2.5).
25
 The binding occurs through a conserved IN-
binding domain (IBD) found within the C-terminal portion of the larger 
p75 LEDGF splice variant. The IBD is essential for stimulation of IN 
activity in vitro and for LEDGF/p75 function during HIV-1 infection.
26
 
LEDGF/p75 might therefore act as a critical costimulator of IN 
activity.
27
 Ectopically expressed HIV-1 IN is degraded by the 
proteasome in human cells, and LEDGF/p75 significantly increases its 
stability. The HIV-1 PIC can be degraded by the proteasome, so the IN-
LEDGF/p75 interaction might help maintain PIC integrity during 
infection. The functional HIV-1 and feline immunodeficiency virus PICs 
































Figure 2.5 Region of the CCD interaction with IBD.  
Adapted from: Reddy KK,   Singh P and   Singh SK. Blocking the interaction 
between HIV-1 integrase and human LEDGF/p75: mutational studies, virtual 
screening and molecular dynamics simulations. Mol. BioSyst. 2014;10, 526-
536. 
 
Alternatively, LEDGF/p75 might function as an obligate chromatin 
acceptor for the PIC. This hypothesis indicates that LEDGF/p75 
intimately associates with chromatin, and its N-terminal PWWP domain 
and AT-hook (ATh) DNA-binding motifs, which mediate chromatin 
binding, are required for HIV-1 infection.29 
It was identified the NMR structure of the integrase-binding domain 
(IBD) in LEDGF and identified amino acid residues essential for the 
interaction. The IBD is a compact right-handed bundle composed of five 
alpha-helices. Based on folding topology, the IBD is structurally related 
to a diverse family of alpha-helical proteins that includes eukaryotic 
translation initiation factor eIF4G and karyopherin-beta. LEDGF 
residues essential for the interaction with IN were localized to 
interhelical loop regions of the bundle structure. Interaction-defective IN 
mutants were previously shown to cripple replication although they 
retained catalytic function. The initial structure determination of a host 








for understanding enzyme-host interactions important for viral 
replication. 
 
2.2 Integrase inhibitors 
 
Until now, only inhibitors targeting the catalytic site of IN with a 
specific effect on strand-transfer process (INSTIs) have been identified 
and developed.
30
 In 2007, the INSTI Raltegravir became the first IN 
inhibitor approved for use in the treatment of HIV infected patients.
31
 
More recently, the FDA also approved Stribild, a single-tablet regimen 
HIV medication containing four drug combination of Elvitegravir, 
another HIV INSTI, Cobicistat, a CYP3A inhibitor, and Emtricitabine 







Figure 2.6 Conventional drugs approved by the FDA for the treatment in 
patients with HIV. a) Raltegravir; b) Elvitegravir; c) Tenofovir; d) 
Emtricitabine; e) Cobicistat. 
 
However, the emergence of the resistance to these drugs gives raise to 
the pressing need of novel IN inhibitors.
33 
Absence of information on the 








the PIC composition and operation complicates and slows the search for 
novel IN inhibitors.  
To overcome these drawbacks, targeting allosteric sites of the protein 
including interaction site of IN with cellular co-factor essential for 
integration, for example the LEDGF/p75-IN interaction, or 
oligomerization/multi oligomerization sites might represent alternative 




2.2.1 Integrase allosteric inhibitors 
 
The design and development of compounds targeting integrase in a 
different way open a route to bypass the cross-resistance problematic of 
INSTIs. 
Recently, a structure-based design approach resulted in the discovery of 
2-(quinolin-3-yl)acetic acid derivatives.
35
 These first class of IN 
inhibitors are named “LEDGINs” since these compounds bind in the 
LEDGF/p75 binding pocket of IN and block the interaction of 
LEDGF/p75 with IN. LEDGINs likely also affect the catalytic activity 
of IN, since LEDGF/p75 binding allosterically modulates integrase 
activity. As a consequence, LEDGINs potently inhibit HIV replication in 
cell culture.
36,37,38 Other studies have shown that Ledgin show an 
additive effect with INSTI. The binding site of the LEDGF/p75 is 
localized at the interface of the IN monomer-monomer, involving both 




In fact, a study of LEDGIN-7, which mimics the amino acid sequence 









Other peptides derived from LEDGF/p75, which have amino acid 
sequence 353-378, 361-370, 402-411, hexhibited in vitro inhibitory 
activity for both binding IN-LEDGF/ p75 and the tetramerization of IN. 
In particular, this effect has been suggested since the peptides showed 
inhibition in the presence and in the absence of LEDGF/ p75. 
Therefore, the formation of the tetramer, represent a very interesting 
target for the development of new allosteric inhibitors.  
 
2.2.2 Integrase tetramerization inhibitors 
 
The first approach to the inhibition of integrase oligomerization process 
resulted the development of two peptides derived from the interface of 
the dimer IN CCD: INH1 (ATGQETAYFLLKLAGKA) and INH5 
(DQAEHLKTAVQMAVFIHNYKA). 
The first reproduces the amino acid sequence of the helix α1 (aa 93-
107), the second reproduces the α5 helix and part of the loop which 
separates the α4 and α5 helices (aa167-187) (Figure 2.7). Experimental 
studies confirmed the dissociation of the tetramer by a INH1 and INH5, 





Figure 2.7 Structure of the catalytic domain dimerization of HIV-1 IN. The two 
monomers are shown in red and blue. The propellers a1 and α5, from which 
the inhibitory peptides INH1 and INH5 respectively, are indicated with the α3 
helix. Adapted from: Maroun RG, Gayet S, Benleulmi MS, Porumb H, 
Zargarian L, Merad H, Leh H, Mouscadet JF, Troalen F, Fermandjian S.  
 




Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. 
Biochemistry. 2001; 40: 13840-13848. 
 
Other studies, have led to the identification of two peptides, NL6 
(TAYFLLKLAGRW) NL9 (ACWWAGIKQEF), with low values of 
IC50 for IN inhibition. These derived from the α1 helical domain (NL6) 
and α3 helical domain respectively (NL9) (figure 2.8) .
 
 
Figure 2.8 IN secondary structure. The peptides derived from α1 (NL6) and α3 
(NL9). Adapted from: Al-Mawsawi LQ, Neamati N. Allosteric inhibitor 
development targeting HIV-1 integrase. Chem. Med. Chem. 2011; 6: 228-41. 
 
To determine the minimal active sequence, based on these sequences 
have been designed other peptides, only NL6-5 (YFLLKL), which 
contains the 6 central residues of NL6, has retained inhibitory activity. 
Furthermore they were synthesized analogues of NL6 and NL9 peptides 
with the amino acid sequence is inverted (RNL6, RNL9) and with the 
replacement of L-amino acids with D-amino acids (DNL6, RDNL6, 












2.2.3 Integrase inhibitors derived from N-terminal domain 
 
The N-terminal integrase plays an important role in the formation of 
tetramer integrase process. Therefore, this domain represents an 
important target for the design of drugs for inhibition of IN 
oligomerization process. In this context, compounds that target the IN N-
terminal domain would be effective at disrupting IN function through a 
range of mechanisms, including allosteric or oligomerization inhibition. 
Recently, considering the amino acid sequence (1-50) of the N-terminal 
domain of integrase, the peptides NZ-1, NZ-2, N-ITFcc and NZ-4 were 
synthesized. Biological assays showed that peptide N-ITFcc, 
corresponding to the third α-helix (FNLPPVVAKEIVAS), inhibits viral 
replication almost 80%, indicating a possible use as an antiviral drug.
43
 
Thus, we considered this domain an important starting point for the 
identification of peptide inhibitors in order to clarify some points on IN 
function in viral replication, such as the elucidation of HIV-1 IN 
polymerization state, or its potentiality in the structure-based design.  
In my PhD project, we present the design and synthesis of peptides 
targeting the integration events by directly inhibiting IN or its 
multimerization process. The synthesized peptides were assayed in vitro 
for their ability to inhibit IN strand transfer activity and for the capability 
to inhibit IN dimerization or to promote IN multimerization. Finally, the 
most potent compounds, conveniently conjugated with cell-penetrating 
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The main goals of this project were been the design and synthesis of 
peptides and peptidomimetics able to inhibit the activity of IN. 
Subsequently, the development of these compounds was based on: a) 
elaboration of a pharmacophoric model concerning the activity of the 
studied peptides; through the combination of synthetic methods and 
conformational analysis, b) optimization of the biological potency and 
selectivity to identify the lead compounds by multiple cycles of design-
synthesis-biological evaluation, c) design and synthesis of new 
molecules with reduced conformational freedom, in which the postulated 
pharmacophoric conformation would be highly probable. 





3.1.1 Design of peptides derived by the sequence NTD IN 1-50 
 
Starting from HIV-1 IN NTD, we synthesized an overlapping peptide 
library to generate a library of peptide sequences of specific length and 
specific offset, to cover the entire native protein sequence NTD IN 1-50 
(peptides 1-15, figure 3.1). The solution structure of NTD has been 
solved by 3D and 2D NMR spectroscopy, classifying NTD as an “helix-
turn-helix” structure. Indeed, it consists of three α helices, which range 
from residues 6–15, 19–25 and 31–39, stabilized by a Zn
2+ 
ion 











part of the hydrophobic core, which explains their importance for 
structural integrity.
1
 As showed in figure 3.1, peptide 2
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α-helix respectively, while 
peptide 11 forms the 3
rd 
α-helix of the NTD, and incorporates the Cys
40
 
of the HHCC motif. In this section we focused on peptide 11. 
 
 
Figure 3.1. Sequences of the designed peptides in this study.  
Adapted from: Sala M, Spensiero A, Esposito F, Scala M C, Vernieri E, 
Bertamino A, Manfra M, Carotenuto A, Grieco P, Novellino E, Cadeddu M, 
Tramontano E, Schols D, Campiglia P, Gomez-Monterrey I M. Development 
and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of 
the N-Terminal Domain of HIV-1 Integrase. Frontiers in Microbiology, 
Virology. 2016; 7, 845. 
 
The relevance of both a α-helix structure and a Zn
2+
 chelating group on 
the inhibitory activity was assessed by the synthesis of three peptides 
derived from peptide 11, in which the Cys residue was deleted (peptide 





 The same His was also used to replace the 
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3.1.2 Biochemical studies: HIV-1 IN catalytic activity inhibition 
(peptides 1-18) 
 
The synthesized peptides 1 to 18 were tested in vitro by the company 
Express Biotech International, for their ability to inhibit the HIV-1 IN. 
Results showed that peptide 18 was the most potent of the series and 
inhibit the HIV-1 IN activity with an IC50 values of 4.5 µM (Table 3.1). 
Peptides 9 and 12 containing the VVAK and VA fragments of peptide 
18, respectively, and peptide 2, which includes the 6-13 fragment of the 
first α-helix, maintained a certain inhibitory activity. In this assay, we 
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Table 3.1 Sequence, analytical data and effect of peptides 1-18 on HIV-1 IN 
activities. 








FLDGIDKAQD 4.70 1163.1 NA 
2 
4
GIDKAQDEHE 5.03 1182.5 162±9 
3 
7
KAQDEHEKYH 4.63 1326.7 NE 
4 
10
DEHEKYHSNW 4.75 1385.5 NA 
5 
13
EKYHSNWRA 5.02 1363.7 NE 
6 
16
HSNWRAMASD 2.94 1215.5 NE 
7 
19
WRAMASDFNL 2.30 1251.7 NE 
8 
22
MASDFNLPPV 1.30 1131.6 NA 
9 
25
DFNLPPVVAK 3.70 1140.6 213±12 
10 
28
LPPVVAKEIV 4.40 1105.8 NA 
11 
31
VVAKEIVASC 2.12 1059.7 NA 
12 
34
KEIVASCDKC 3.06 1136.5 477±23 
13 
37
VASCDKCQLK 2.80 1135.5 NA 
14 
40
CDKCQLKGEA 2.60 1135.4 NA 
15 
43
CQLKGEAM 3.70 920.3 NA 
16 
31
VVAKEIVAS 2.50 956.5 NA 
17 VVAKEIVASH 5.22 1094.0 NA 
18 VVAKEIVAH 3.50 1007.0 4.5±0.9 
Ral.    0.18±0.01 
 
All peptide are acetylated and amidate at N-terminal and C-terminal respectively. 
k‟ [(peptide retention time – solvent retention time)/solvent retention time]. Peptide concentration 
µM. 
NE = No effect. The peptide demonstrated no significant effect in the IN assay, where the 
percent activity for the compounds was found to be 100% ± 75%  
NA = Not Applicable, 50% inhibition by the compound was not achieved 
 
3.1.3 Design of peptides 19-21 containing the Phe residue and                 
Ala- scanning approach (peptides 22-28) 
 
Base on the ability of inhibiting HIV-1 IN showed by peptide 18, we 
synthesized three peptides, in which Val at position 1, 2, and 7 was 
substituted with Phe (peptides 19, 20, and 21, respectively). Indeed, Phe 
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and have different hydrophobicity degree.
4,5 
In addition, Phe could be 
involved in additional stacking interactions with the viral target. 
Subsequently, we established the contribution of the various amino acid 
residues to the antiviral activity of peptide 18 (peptides 22-28) through 
an L-Ala scanning analysis.  
 
3.1.4 Biochemical studies: HIV-1 IN catalytic activity inhibition 
(peptides 19-28) 
 
The results of the biochemical evaluation of peptides 19-28 are 
summarized in Table 3.2 Replacement of the Val residue for the bulky-
aromatic Phe led to a strong reduction of the activity of the 
corresponding peptides 19-21 compared with 18, indicating the 
importance of this ramified amino acid on the HIV-1 IN inhibition 
capability. This result was also confirmed with the data from the Alanine 







by Ala produced a dramatic loss of the HIV-1 IN inhibitory activity of 
the corresponding analogues (22, 23, and 27). The most interesting result 





, respectively, produced only a weak decrease of 
HIV-1 IN inhibitor ability if compared to the hit peptide, suggesting that 
a lack of polar side chains in these positions or the introduction of low 
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18 VVAKEIVAH 3.50 1007 4.5±0.9 
19 FVAKEIVAH 4.40 1054.4 NA 
20 VFAKEIVAH 4.50 1054.5 375±19 
21 VVAKEIFAH 4.20 1054.2 504±22 
22 AVAKEIVAH 3.90 978.6 NA 
23 VAAKEIVAH 4.20 978.4 NA 
24 VVAAEIVAH 4.84 949.5 20.8±1.3 
25 VVAKAIVAH 4.05 948.6 13.0±1.0 
26 VVAKEAVAH 1.39 964.5 NA 
27 VVAKEIAAH 3.90 978.5 NA 
28 VVAKEIVAA 4.89 939.5 NA 
Ral.    0.24±0.02 
All peptide are acetylated and amidate at N-terminal and C-terminal respectively 
k‟ [(peptide retention time – solvent retention time)/solvent retention time]. Peptide concentration 
µM 
NA = Not Applicable, 50% inhibition by the compound was not achieved (as example see the 
dose-response curve of peptide 19 in SI)   
 
3.1.5 Conformational Studies on peptides 22-28 
 
Circular Dichroism was used to determine the conformation of peptide 
18 and its analogues (22-28). Analysis of spectra acquired in water 
solution indicated that all peptides are random coil in water (data not 
shown). In contrast, spectra acquired in 50% TFE/water solution (TFE, 
trifluoroethanol) indicate that peptides have high tendency to fold as α 
helix in fluoroalcohol solution (figure 3.2). In particular, all peptides 
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Figure 3.2 CD Spectra of selected peptides in TFE/water 50% solution. 
Peptide are represented in: 18 (solid blue line), 22 (solid red line), 23 (solid 
black line), 24 (solid purple line), 25 (dashed black line), 26 (solid orange 
line), 27 (dashed blue line), 28 (dashed red line). Adapted from: Sala M, 
Spensiero A, Esposito F, Scala M C, Vernieri E, Bertamino A, Manfra M, 
Carotenuto A, Grieco P, Novellino E, Cadeddu M, Tramontano E, Schols D, 
Campiglia P, Gomez-Monterrey I M. Development and Identification of a 
Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain 
of HIV-1 Integrase. Frontiers in Microbiology, Virology. 2016; 7, 845. 
 
3.1.6 IN-IN dimerization and IN multimerization studies on peptide 18, 
24 and 25 
 
Taking in consideration that these peptides represent fragments of NTD 
domain, which is involved in different and essential process of the IN 
activity,
6,7
 we wondered whether they were able to inhibit the IN-IN 
dimerization or stabilizing the IN in the multimeric form. In fact, it has 
been reported that allosteric compounds inhibit IN activity binding a site 
that is different from CCD binding site and working as disruptors of the 
IN dimer formation.
8
 In collaboration with Prof. Enzo Tramonano at 
University of Cagliari, to verify whether active peptides 18, 24 and 25 
can modulate the dynamic interplay between IN subunits, we tested 
them using an HTRF-based IN subunit exchange assay. In this assay two 
IN preparation are used: a first His-tagged IN preparation, and a second  
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Flag-tagged IN preparation. In both preparations the purified IN is at 
equilibrium as a dimer; such dimers go through monomers exchange.  
Hence, in the assay the monomer exchange of the two different 
preparations leads to the formation of a dimer with one His-tagged 
subunit and one Flag-tagged subunit. The formation of this “hybrid” 
dimer can be monitored in the HTRF-based assay as described.
9,10
 When 
the assay is performed in the presence of a compound inhibiting 
dimerization, the HTRF signal decreases as the concentration of 
compound increases, whereas in the presence of a compound promoting 
IN multimerization (association of dimers) the HTRF signal increases as 
the concentration of the compound increases. We found that peptides 24 
and 25 modulate the interactions between the IN subunits in different 
manners using the allosteric inhibitor LEDGIN-6 as a control (Table 
3.3). In fact, peptide 24 was able to inhibit the IN-IN dimer formation 
with an IC50 value of 32 µM, but did not affect IN multimerization, 
while peptide 25 promoted IN multimerization, with a concentration of 
compound stimulating the Multimerization Increase by 50% (MI50 
value) of 4.8 µM, but did not inhibited IN multimerization. While the 
reason for this different behavior was not clear, it demonstrates that IN 
multimerization can be differently modulated by interfering with the 
NTD sequence. Differently, peptide 18 was not able to modulate the 
dimer/multimer formation. Hence, the three peptides showed three 
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Table 3.3 Effects of peptides 18, 24, and 25 on the HIV-1 IN dimerization and 














 >100 (100%) 
24 VVAAEIVAH 32 ± 3 >100 (100%) 
25 VVAKAIVAH >100 (100%) 4.8 ± 0.4 
LEDGIN-6 
 
>100 (100%) 10 ± 1 
a Compound concentration required to inhibit the HIV-1 IN-IN subunit exchange by 50%. 
b Percentage of control measured in the presence of 100 µM concentration. 
c Compound concentration required to inhibit the multimerization increase by 50%. 
 
3.1.7 Cell-based HIV replication assay on the most active peptides 18, 
24 and 25 
 
In collaboration with Prof. Dominique Schols at University of Leuven, 
the most potent peptides 18, 24 and 25, conveniently conjugated with the 
cell-penetrating fragment TAT, were evaluated for their capability to 
inhibit the HIV-1 replication in CD4
+
 MT-4 cells (Table 3.4). The 
conjugated peptides 18 and 24 were devoid of antiviral activity when 
evaluated against HIV replication. In contrast, 25 showed marked 
inhibitory potency with good selectivity against HIV-1 (IC50 value in the 
low micromolar range, accordingly with the results on IN catalysis and 
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Table 3.4. Evaluation of the synthesized peptides against HIV-1 and HIV-2 
















TAT-18 4.31 2568.05 > 105 > 105 105 
TAT-24 3.56 2510.96 > 50 > 50 > 50 
TAT-25 4.50 2510.02 4.0 ± 
0.6 
> 21.4 21.4 ± 2.0 





a 50% Effective concentration, or compound concentration required to inhibit HIV-induced 
cytopathogenic effect in MT-4 cell culture. 
b Compound concentration required to reduce by 50% MT-4 cell viability. 
*GRKKRRQRRRPQ: TAT  
 
3.1.8 Structure-activity relationship studies on peptide 25 
 
During my PhD project, the structure-activity relationship of the peptide 
25 was examined, focusing on the following points: 
 
Evaluation of the role played by each aminoacid residue 
configuration for interaction of the peptide with IN (D-scan 
analysis). It‟s well known peptides may adopt secondary structures, 
which are responsible for their receptor affinity and biological activity. 
Although specific synthetic modifications of particular residues may 
reveal information on the receptor-bound conformer, combinatorial 
scanning strategies, in which each residue in a sequence is 
systematically modified, offer enhanced means for identifying the 
location of key residues and the global structural requirements for 
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Information on the importance of native residues and their systematic 
modifications are respectively obtained from observed losses and 
improvements of activity on evaluation of the analog libraries from 
peptide scanning. In particular, the importance of amino acid 
configuration on biological activity can be determined by systematic 
substitution of each residue with its enantiomer (typically wild-type L- 
for D-amino acid). Consequentely, to have insights about the importance 
side-chain chirality of aminoacid residue, as well as information about 
certain conformations that might be important for peptide–integrase 
interactions, a D-scan analysis of peptide 25 was performed. We 
synthesized a new library of peptides (29-37, Table 3.5) containing the 
corresponding D-aminoacid and evaluated for their capability to inhibit 
IN activity. 
 
Study of the importance of amino acid sequence. In order to verify if 
the amino acids sequence, rather than the amino acid composition, is 
important for activity, we synthesized the scramble peptide (peptide 38, 
Table 3.5).  
In addition, we synthesized peptide 39 containing the residues 25-39 of 
the 3
rd
 alpha helix of N-teminal domain of integrase. This fragment, 
known in literature for its activity of viral replication inhibition, includes 
the sequence of peptide 25.
12
 
So peptide 39 could be useful to a comparison study. 
 
Identification of minimum active sequence through deletion at              
N- and C-terminal. Truncation library can be used to identify the 
shortest aminoacid sequence needed for the peptide activity. The 
truncation process is carried out via a systemic reduction of residues 
from each flank of the original peptide. For this reason, we synthesized  
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peptides 40-43 (Table 3.5) obtained from deletion of two amino acids at 
the N-terminal and C-terminal of peptide 25.  
 
3.1.9 Biochemical studies: HIV-1 IN catalytic activity inhibition and 
IN-IN dimerization and IN multimerization studies on peptides 29-39 
 
The synthesized peptides (29-39) were tested on HTRF assay to evaluate 
the catalytic activity in presence of LEDGF/p75 protein. In this assay, 
Raltegravir was used as a control. Furthermore, to verify whether 
peptides can modulate the dynamic interplay between IN subunits, we 
tested them using an HTRF-based IN subunit exchange assay. As shown 
in Table 3.5 all peptides are not able to modulate the dimer/multimer 
formation and neither of peptides inhibits catalytic activity of integrase 
as peptide 25. The results obtained, confirmed peptide 25 as a hit for 
further development of new chemotherapeutic agents against HIV-1.
13
  
Studies to evaluate the antiviral activity of trunks peptides (40-43) are 
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Table 3.5  Effects of peptides 1, 4, and 5 on the HIV-1 IN dimerization and 
multimerization process, and effects on the HIV-1 IN LEDGF-dependent and – 
independent catalytic activity. 
 
 
a Compound concentration required to inhibit the HIV-1 IN-IN subunit exchange by 50%. 
b Compound concentration required to inhibit the multimerization increase by 50%. 
All peptide are acetylated and amidate at C terminal and N terminal respectively 
k‟ [(peptide retention time – solvent retention time)/solvent retention time]. Peptide concentration 
µM 
 
3.1.10 NMR analysis on peptides 25 and 39 
 
In collaboration with Dr. M. Angeles Jimenez at University of Madrid, 
we evaluated the conformation of peptide 25 and peptide 39 by NMR 
analysis. We found that two peptides in aqueous solution are within the 
random coil range (|ΔδCα| ≤ 0.5 ppm, and |ΔδCβ| ≤ 0.5 ppm), and the 
ΔδHα values are only slightly outside the random coil range (|ΔδHα| ≤ 
0.05 ppm). While, in the presence of TFE the magnitudes of ΔδHα, 
ΔδCα and ΔδCβ increase significantly, being ΔδHα and ΔδCβ negative 















25 VVAKAIVAH 3.50 948.6 13.0 ± 1.0 >100 
(100%) 
4.8 ± 0.4 
29 vVAKAIVAH 4.40 948.6 >100 (100%) ND ND 
30 VvAKAIVAH 4.50 948.6 >100 (52%) ND ND 
31 VVaKAIVAH 4.20 948.6 >100 (82%) ND ND 
32 VVAkAIVAH 3.90 948.6 >100 (59%) ND ND 
33 VVAKaIVAH 4.20 948.6 >100 (100%) ND ND 
34 VVAKAiVAH 4.84 948.6 >100 (59%) ND ND 
35 VVAKAIvAH 4.05 948.6 94 ± 4.0 ND ND 
36 VVAKAIVaH 1.39 948.6 >100 (55%) ND ND 
37 VVAKAIVAh 3.90 948.6 >100 (61%) ND ND 
38 AKVAVAHIV 4.89 948.6 89.5 ± 0.5 ND ND 




40 VVAKAIV 3.45 739.94 - - - 
41 VVAKA 3.12 527.64 - - - 
42 AKAIVAH 3.56 749.89 - - - 
43 AIVAH 3.76 550.64 - - - 
LEDGIN-6 -   9 ± 2 >100 
(100%) 
10 ± 1 
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This indicates that the two peptides form a helix structure in the presence 
of TFE. The populations of helix estimated on the basis of the averaged 
ΔδHα value observed in 30 % TFE are 77 % for peptide 25 and 56 % for 
peptide 39. To visualise the structural features of the helices formed by 
peptides 25 and 39 in the presence of TFE, we performed structure 
calculations. We found that short peptide 25 shows an α-helix extending 
throughout all its residues, which is very well defined. Peptide 39 also 
exhibits a well-defined structure, but it displays a non-regular structure 
in segment 1-5, and an α-helix spanning residues 6-15 (figures 3.3). 
 
  
Figure 3.3 (1) NMR structures of peptides 25(A and B) and 39 (C and D) in 30 
% TFE. (2) Overlay of the NMR structure of peptide 25 onto the NMR 
structure of peptide 39. (A) Backbone atoms for 25 are in blue and for 39 in 
black. (B) Backbone atoms for 25 are in cyan and side chains in blue, and for  
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39 backbone in grey and side chains in black. (C) Ribbon representation of the 
overlay of representative conformers of 25 (in cyan) and 39 (in red). 
 
3.2 Improvement of pharmacokinetic properties on peptide 25 
 
To improve pharmacokinetic properties of peptide 25, so in order to 
identify the most active and at the same time the most stable peptide, we 
design cyclic peptides, using two different approaches. It‟s well known 
that cyclic peptides are more resistant to proteolysis than their linear 
counterparts due to the lack of exopeptidase cleavage sites. 
 
3.2.1The head-to-tail cyclization approach 
 
Head-to-tail peptide cyclization is well-know strategy to constrain the 
high flexibility of linear peptides inducing or stabilizing the bioactive 
conformation of peptides and allows us to have a peptide with minor 
possible conformers.
14
 On the basis of these observations, we 
synthesized peptide 44 (figure 3.4). Studies to evaluate the antiviral 
activity of the cyclic peptide 44 are still in progress. 
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Figure 3.4 The cyclic peptide 44. 
 
3.2.2 Insertion of a lactam bridge on peptide 25 (peptides 45-46) 
 
An approach for stabilizing peptides is the incorporation of covalent or 
not covalent linkages between constituent aminoacid side chains. In this 
case we designed and synthesized analogues of peptide 25 characterized 
by the introduction of a lactam bridge resulting in peptides 45-46 (figure 
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Figure 3.5 Cyclic peptide 46 with the lactam bridge. 
 
In particular, we replaced the aminoacid residue Histidine at positions 9 
with carboxylic (Asp or Glu) functions on the side chain.  
Therefore the lactam bridge was obtained by the bond between the side 
chains of Asp or Glu with Lys in position 4. Studies of cyclic peptides 
are still in progress. 
 





45 VVA[KAIVAE] 4.35 880.09 
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3.3 Chemistry  
 
3.3.1 General procedure for synthesis  
 
The synthesis of peptides (1-46) was performed according to the solid 
phase strategy, using standard Fmoc methodology in a manual reaction 
vessel.
15
 The first amino acid, was linked to the Rink resin previously 
deprotected by a 25% piperidine solution in N,N-dimethylformamide. 
The following protected amino acids were then added stepwise. Each 
coupling reaction was accomplished using a 3-fold excess of amino acid 
with HBTU and HOBt in the presence of DIPEA. The Nα-Fmoc 
protecting group was removed by treating the protected peptide resin 
with a 25% solution of piperidine in DMF. Kaiser test was performed 
step to step to confirm the complete removal of the Fmoc protecting 
group and the complete coupling reaction. The N-terminal Fmoc group 
was removed as described above and the peptides were acetylated 
adding a solution of Ac2O/DCM. Finally, the peptides were released 
from the resin with trifluoroacetic acid (TFA/TES/H2O) for 3 h. The 
resin was removed by filtration, and the crude peptides were recovered 
by precipitation with cold anhydrous ethyl ether to give a white powder 
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3.3.2 Synthesis of head-to-tail cyclic peptide 44: side reaction during 
the sequence assembly 
 
During the past years, great effort has been made to develop more 
efficient methods for the synthesis of cyclic peptides. The use of solid 
phase assembly on an acid labile linkers have allowed detachment of 
peptide from the polymer without sacrificing side-chain protection. In 
this context the 2-chlorotrityl resin and the 4-hydroxymethyl-3-
methoxyphenoxybutyric acid linker are most used as solid support. An 
alternative method involves the use of the oxime resin. 
Initially, we chosen the  2-chlorotrityl chloride resin for the synthesis  of 
head to tail cyclic peptide, peptide 44. The first N--Fmoc amino acid         
Fmoc-His(Boc)-OH and DIPEA were dissolved in dry dichloromethane 
containing, if necessary, a small amount of dry DMF (enough to 
facilitate dissolution of the acid). This latter, was added to the resin and 
stirred for 2-4 h. Then the loading test was carried out. Other N -Fmoc 
amino acids were sequentially coupled as previously described. The final 
cleavage with TFA 1% in DCM resulted in protected peptides. 
 
 
A solution of the linear protected peptide in DMF was added at room 
temperature to a reaction flask containing a solution of N-
hydroxybenzotriazole (HOBt), HBTU and DIPEA in DMF. The mixture 
was stirred for 24 h at room temperature and monitored by TLC. 
However this strategy was failed.
 16
 The stretching of the sequence was 
monitored by test cleavage an LC-MS and we observed, during the 
second aminoacid deprotection, a premature cleavage of the C-terminal 
acid peptides. This could be interpreted as diketopiperazine formation 




Chapter III: Design, synthesis, biological evaluation and conformational 
studies of peptides derived from N-terminal domain HIV-1 integrase 
61 
 
In peptide synthesis the  formation of diketopiperazine is a notorious 





Figure 3.7 Schematic representation of diketopiperazine formation. 
 
As described in literature, we hypothesized that  during the base-induced 
deprotection of the second amino acid, the free amino function attacks 
the carbonyl group leading to diketopiperazine formation (nucleophile 
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Figure 3.8 Schematic representation of the cyclic peptide synthesis. 
 
To maintain the orthogonal strategy, and try to obtain the desired 
sequence in a good yield another approach was evaluated. So we  
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performed the peptide 44 synthesis using a base labile and orthogonally 
compatible linker, HMBA (4-Hydroxymethylbenzoic acid).  
The cyclic peptide was synthesized on a TentaGel-S-NH2 resin. 
Coupling reaction of HMBA Linker was performed using coupling 
reagents HBTU, HOBt and DIEA in DMF at 60 ºC. The first amino acid, 
N𝛼-Fmoc amino acid, was attached to the HMBA linker using 
HOBt/HBTU as activating agents and a catalytic amount of DMAP. In 
addition, after each step of deprotection and after each coupling step, 
Kaiser test was performed. N-terminal Fmoc group was removed as 
described above. Then, the peptide was released from the resin with 
NaOH/Dioxane for 15 min. To neutralize NaOH we used a 0.1 M HCl 
solution. The resin was removed by filtration, and the crude peptide was 
recovered by lyophilization.  
In these conditions, we observed the formation of two peptides: the 
unprotected peptide and the desired one with a no detectable yield, 
indicating the detachment of  Boc protecting groups present on the side 
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Finally, Fmoc-His(Allyl)-Trityl resin was used to avoid the collateral 
reactions above discussed. The following protected amino acids were 
then added stepwise. Each coupling reaction was accomplished using a 
HBTU and HOBt as coupling reagents in the presence of DIEA. The 
N𝛼-Fmoc amino acids protecting groups were removed by treating the 
protected peptide resin with a 25% solution of piperidine in DMF.  
The Allyl groups was removed according to strategy reported by Grieco 
et al.
18
 The last Nα -Fmoc was removed and the macrocyclic lactam ring 
formation was mediated by addition of HBTU, HOBt and DIPEA for 2 
h. The process was repeated if necessary. Subsequently, the peptide was 
released from the resin with TFA/H2O (50:50) for 3 h. The resin was 
removed by filtration, and the crude peptide was recovered by 
precipitation with cold anhydrous ethyl ether to give a white powder and 
then lyophilized (figure 3.10). 
Using this approach we obtained the desired cyclic peptide with a yield 
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Figure 3.10 Schematic representation of the cyclic peptide synthesis. 
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3.3.3 Synthesis of lactam analogues (peptides 45-46)  
 
The corresponding linear peptides were synthesized as described in the 
paragraph 3.1. The amino acids N-Fmoc-Asp(Allyl)-OH, N-Fmoc-
Glu(Allyl)-OH and N-Fmoc-Lys(Alloc)-OH were used as lactam 
precursors. After linear assembly, the N-Alloc and the Allyl groups 
were removed according to strategy reported by Grieco et al.
18
 The 
macrocyclic lactam ring formation was mediated by addition of HBTU, 
HOBt and DIPEA for 2 h.  The process was repeated if necessary 
(Kaiser test was used to monitor completion). The N-terminal Fmoc 
group was removed and the peptide was released from the resin as 
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All crude peptides were purified by RP-HPLC on a preparative C18-
bonded silica column using a Shimadzu SPD 10A UV/VIS detector, 
with detection at 215 and 254 nm. All peptides were characterized with 
analytical RP-HPLC and peptides molecular weights were determined 
by ESI mass spectrometry in a MS Thermo Quest Finnigan LTQ 





A library of peptides (1-15) was developed from the NTD sequence (1-
50) by using a mimotopic strategy. Preliminary results of the in vitro 
integrase assay indicated that the fragment VVAKEIVAH (peptide 18), 
which includes a His residue instead of the natural Ser at position 39, 
reduced significantly the HIV-1 IN activity showing an IC50 value of 4.5 
µM. Peptide 18 is included into the sequence of the 3
rd 
α-helix of the 
NTD, which is located on the dimerization interface within the context 
of the crystal structure of this domain.
6
 Accordingly, we observed 
significant changes in potency of this peptide when lipophilic and 









 are substituted.  Ala scanning showed also that 
loss of a lysine positively charge or a glutamate negatively charge does 
not modify substantially the inhibitory activity of the resulting peptides 
(24 and 25, respectively). According to the circular dichroism results, 
the inhibitory activity of these compounds does not seem to be related to 
their ability to form helical structures. In fact, inactive peptides 22, 23, 
26, 27 and 28 all show similar helical content as 18 and 24. On the other 
hand, compound 25 shows a significant reduction of helical tendency but  
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is approximately as active as 18. Recently, an approach to develop new 
HIV-1 IN inhibitors that bind in a pocket different from the active 
binding site, lead to the discovery of new drugs that are able to interfere 
with the IN dynamic interplay, in two possible ways.
  
In the first one, the 
molecules interfere with the IN dimer-dimer formation, while the 
second, the molecules promote the IN multimerization. In this case, IN is 
trapped in a multimeric form in which the movements of the individual 
subunits are restricted, and, as a consequence, also the catalytic process. 
We tested peptides 18, 24, and 25 on HTRF assays to determine their 
potential mechanism of actions and to verify whether they were capable 
to inhibit the HIV-1 IN. Peptide 24 was able to inhibit the IN-IN dimer 
formation, while peptide 25 stabilizes the multimeric form of IN. 
Differently, peptide 18 was not able to modulate the dimer/multimer 
formation. These data suggest that the modulation of IN dimerization 
and/or multimerization process could be determined by the net charge of 
the synthesized peptides, or more specifically by their ability to form 
intermolecular salt bridges between Glu
5
 (peptide 24) or Lys
4 
(peptide 
25) residues and Lys or Asp/Glu residues of different subunits, 
respectively.
19,20
 This hypothesis, however, is less probable for peptide 





 prevents their interactions with acid and 
basic residues of other subunits. In this case, the in vitro inhibitory 
activity of peptide 18 could be related to its ability of inhibiting IN-DNA 
interactions.  
Interestingly, peptide 25, conjugated with the cell-penetrating Tat 
fragment, is the only compound into this series able to inhibit the HIV-1 
induced cytopathogenic effect in MT-4 cell. Our results indicate that the 
presence of a negative charge (Glu
5
 side chain) is detrimental for the  
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inhibition of HIV replication in target CD4 T cells (analogues 18 and 
24), while the positively charged Lys
4
 residue (peptide 25) plays an 
important role in the potential antiviral activity. In addition, this peptide 
has shown to have potent and selective antiviral activity for HIV-1. 
Although the antiviral activity is about 5-fold lower than the 
concentration of its cellular toxicity, peptide 25 represents a suitable lead 
compound for the development of novel derivatives with improved 
toxicity profile.  
Overall, our data confirm the hypothesis that peptides derived from the 
protein of interest may be used to identify domains which are important 
for catalytic activity, protein−protein interactions, and/or 
multimerization process.
21,22
 Data obtained reflect also the difficulties in 




In fact, the modification or replacement of a single amino acid in the 
sequence of the most potent compound in this series (peptide 25), 
determines the diminution or loss of the target activity. The 
identification of the amino acid residues implicated in the inhibition of 
IN activity highlights the importance of studies that identify such 
residues and investigates possible roles for them. 
In conclusion, this study shows that the modified 31-39 sequence of the 
N-terminal domain of HIV integrase (VVAKAIVAH, peptide 25) is able 
to interfere with functional integration of the HIV-1 enzyme. This 
peptide conveniently conjugated (peptide TAT-25) inhibits the HIV 
activity in cell culture probably due to its ability to stabilize the IN 
multimeric form. 
Moreover, we confirmed peptide 25 the most powerful of the 
synthesized series, employing of enantiomeric aminoacids, to evaluate  
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factors such as configuration, conformation and hydrogen-bonding for 
activity. Furthermore, we used NMR approach to investigate the 
conformation of the peptide. The results obtained showed a strong alpha 
helix conformation of the peptide 25 which could be essential for 
interaction with IN. This information will be used in future studies to 
design peptide 25 analogs acting as selective IN inhibitors. 
Indeed, our peptide, one of the few in cell active peptides reported to 
date, could be considered as a suitable hit compound in the development 
of novel anti-HIV1 peptidomimetic agents with a mechanism of action 
different to that the approved anti-IN drugs.
24
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3.5 Experimental section 
 




-Fmoc-protected amino acids, Rink amide-resin, HOAt, HOBt, 
HBTU, DIEA, piperidine and trifluoroacetic acid were purchased from 
Iris Biotech (Germany). Peptide synthesis solvents, reagents, as well as 
CH3CN for HPLC were reagent grade and were acquired from 
commercial sources and used without further purification unless 
otherwise noted. 
 
3.5.1.1 Peptide synthesis 
 
The synthesis of IN analogues was performed according to the solid 
phase approach using standard Fmoc methodology in a manual reaction 
vessel and automated microwave synthesizer.
25,26
 




























Fmoc-Ser(tBu)-OH, was linked on to the Rink resin (100-200 mesh, 1% 
DVB, 0.59 mmol/g) previously deprotected by a 25% piperidine solution 
in DMF for 30 min. The following protected amino acids were then 
added stepwise. Each coupling reaction was accomplished using a 3-fold 
excess of amino acid with HBTU (3 eq.) and HOBt (3 eq.) in the 
presence of DIEA (6 eq.). The N
α
-Fmoc protecting groups were removed 
by treating the protected peptide resin with a 25% solution of piperidine 
in DMF (1×5 min and 1x 25 min). The peptide resin was washed three 
times with DMF and the next coupling step was initiated in a stepwise  
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manner. The peptide resin was washed with DCM (3×), DMF (3×), and 
DCM (3×), and the deprotection protocol was repeated after each  
 
coupling step. In addition, after each step of deprotection and after each 
coupling step, Kaiser test was performed to confirm the complete 
removal of the Fmoc protecting group, respectively, and to verify that 
complete coupling has occurred on all the free amines on the resin. The 
N-terminal Fmoc group was removed as described above, and the 
peptides were acetylated adding a solution of Ac2O/DCM (1:3) shaking 
for 30 min. Finally the peptides were released from the resin with 
TFA/iPr3SiH/H2O (90:5:5) for 3 h. The resin was removed by filtration, 
and the crude peptide was recovered by precipitation with cold 
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3.5.2 Synthesis peptide 44 
 
Peptide was synthesized on a Fmoc-His(Allyl)-Trityl resin (0.7 mmol/g), 
previously deprotected by a 25% piperidine solution in DMF for 30 min. 
The following protected amino acids were then added stepwise. Each 
coupling reaction was accomplished using as coupling reagent HBTU 
(3.9 eq, 0.5M), HOBt (4.0 eq, 0.5M) and DIEA (7.2 eq, 0,5M) in DMF. 
The N𝛼-Fmoc protecting groups were removed by treating the protected 
peptide resin with a 25% solution of piperidine in DMF (1 × 5min and 1 
× 25min).  
The Allyl group was removed according to the following procedure: 200 
mg of peptide resin was washed with dichloromethane (DCM) under 
nitrogen and a solution of PhSiH3 (24 equiv) in 2 mL of DCM was 
added. Subsequently, a solution of Pd(PPh3)4 (0.25 equiv) in 6 mL of 
DCM was added and the reaction was allowed to proceed under nitrogen 
for 30 min. The peptide resin was washed with DCM (3x), DMF (3x) 
and DCM (4x), and the deprotection protocol was repeated (3x). The last 
Nα -Fmoc was removed and the macrocyclic lactam ring formation was 
mediated by addition of HBTU (6 equiv), HOBt (6 equiv) and DIPEA 
(12 equiv) for 2 h. The process was repeated if necessary (Kaiser test 
used to monitor completion). Subsequently the peptide was released 
from the resin with TFA/H2O (50:50) for 3 h. The resin was removed by 
filtration, and the crude peptide was recovered by precipitation with cold 
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3.5.3 Synthesis of lactam analogues (peptides 45-46)  
 
The corresponding linear peptides were synthesized as described in the 
paragraph 5.1.1. The amino acids N-Fmoc-Asp(Allyl)-OH, N-Fmoc-
Glu(Allyl)-OH and N-Fmoc-Lys(Alloc)-OH were used as lactam 
precursors. After linear assembly, the N-Alloc and the Allyl groups 
were removed according to the following procedure: 200 mg of peptide 
resin was washed with dichloromethane (DCM) under nitrogen and a 
solution of PhSiH3 (24 equiv) in 2 mL of DCM was added. 
Subsequently, a solution of Pd(PPh3)4 (0.25 equiv) in 6 mL of DCM 
was added and the reaction was allowed to proceed under nitrogen for 30 
min. The peptide resin was washed with DCM (3x), DMF (3x) and 
DCM (4x), and the deprotection protocol was repeated (3x). The 
macrocyclic lactam ring formation was mediated by addition of HBTU 
(6 equiv), HOBt (6 equiv) and DIPEA (12 equiv) for 2 h. The process 
was repeated if necessary (Kaiser test used to monitor completion). The 
N-terminal Fmoc group was removed and the peptide was released from 
the resin as described above. 
 
3.5.4 Purification and characterization 
 
All crude peptides (1-46) were purified by RP-HPLC on a preparative 
C18-bonded silica column (Kinetex 5μ, 100Å, 100×21.2mm) using a 
Shimadzu SPD 10A UV−Vis detector, with detection at 210 nm and 254 
nm. The column was perfused at a flow rate of 20 mL/min with solvent 
A (10%, v/v, water in 0.1% aqueous TFA), and a linear gradient from 
5% to 90% of solvent B (80%, v/v, acetonitrile in 0.1% aqueous TFA) 
over 20 min was adopted for peptide elution.  Analytical purity, was 
determined by RP-HPLC, using an autosampler, with dual wavelength 
absorbance detector with wavelength set to 215 nm, all of which were  
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obtained from Shimadzu. The mobile phases employed were: solvent A 
(water + 0.1% TFA) and solvent B (acetonitrile + 0.1% TFA); using a 
linear gradient from 5% to 90% B over 11 min, fitted with C-18 column 
Phenomenex, Ascentis ES-C18 column (5cm х 3.0mm, 2.7µm), at a 
flow rate of 0.800 mL/min (figure 3.13). ESI mass spectrometry was 
determined using a Finnigan LCQ Deca ion trap instrument, 
manufactured by Thermo Finnigan (San Jose, CA, USA), equipped with 
the Excalibur software for processing the data acquired. The sample was 
dissolved in a mixture of water and methanol (50/50) and injected 
directly into the electrospray source, using a syringe pump, which 
maintains constant flow at 5 μL/min. The temperature of the capillary 
was set at 220 °C  
 
 
Figure 3.12 Analytical HPLC spectrum of peptide 25. 
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3.5.5 IN Activity Inhibition assay  
 
Express Biotech International Company performed this assay using its 
HIV-1 IN Assay kit (Xpressbio Life Science Products, USA. 
www.xpressbio.com).
 
Briefly, Streptavidin coated 96-well plates were 
coated with a double-stranded HIV-1 LTR U5 donor substrate (DS) 
oligonucleotide containing an end-labeled biotin. Full-length 
recombinant HIV-1 integrase protein was then loaded onto this oligo 
substrate. Compounds were added to the reaction and then a different 
double-stranded target substrate (TS) oligo containing 3‟-end 
modifications was added to the plate. The sequence of DS DNA and TS 
DNA substrates used in this assay were 5'-P ACC CTT TTA GTC AGT 
GTG GAA AAT CTC TAG CAG  TGAA AAT CAG TCA CAC CTT 
TTA GAG ATC GTC  A and  5‟  TGA CCA AGG GCT AAT TCA CT 
  ACT GGT TCC CGA TTA GAS GA respectively.
27,28
 
The HIV-1 IN cleaves the terminal two bases from the exposed 3‟-end of 
the HIV-1 LTR DS and then catalyzes a strand-transfer reaction to 
integrate the DS into the TS. The products of the reaction were detected 
colorimetrically using an HRP-labeled antibody directed against the TS 
3‟-end modification. Percent inhibition in the IN assay was calculated 
and IC50 values were determined.  
 
3.5.6 HTRF-based IN Subunit Exchange Assay  
 
Full-length IN and LEDGF proteins were expressed in E. coli  
BL21(DE3) and were purified as described.
9,10,19
 His- and FLAG-tagged 
INs, were mixed in 25 mM Tris (pH 7.4) buffer containing 150 mM 
NaCl, 2 mM MgCl2, 0.1% Nonidet P-40, 1 mg/ml BSA. Test compounds 
were then added to the mixture. A mixture of anti-His6-XL665 and anti-
FLAG-EuCryptate antibodies were then added to the reaction and, after  
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an incubation, the plate are read and the HTRF signal is calculated from                     
the 665 /620 nm ratio. 
 
3.5.7  HTRF LEDGF-dependent and -independent HIV-1 IN assay  
 
The IN LEDGF/p75 dependent assay allow to measure the inhibition of 
3‟processing and strand transfer IN reactions in presence of recombinant 
LEDGF/p75 protein, as previously described. Briefly, 50 nM IN was 
preincubated with increasing concentration of compounds in reaction 
buffer containing 20 mM HEPES pH 7.5, 1 mM DTT, 1% Glycerol, 20 
mM MgCl2, 0.05% Brij-35 and 0.1 mg/ml BSA. To this mixture, 100 
nM DNA donor substrate and 50 nM DNA acceptor substrate and 50 nM 
LEDGF/p75 protein (or without LEDGF/p75 protein) were added and 
incubated at 37 °C for 90 minutes. After the incubation, 4 nM of 
Europium-Streptavidine were added at the reaction mixture and the 
HTRF signal was recorded using a Perkin Elmer Victor 3 plate reader 
using a 314 nm for excitation wavelength and 668 and 620 nm for the 
wavelength of the acceptor and the donor substrates emission, 
respectively. 
 
3.5.8 Circular dichroism (CD) 
 
All CD spectra were recorded using a JASCO J710 spectropolarimeter at 
20°C between λ=260–190 nm (1 mm path, 1 nm bandwidth, 4 
accumulations, and 100 nm min
-1
 scanning speed). Measurements were 
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3.5.9 Cell-based assays 
 
The HIV-1 strain NL4.3 was obtained from the AIDS Research and 
Reference Reagent Program (Division of AIDS, NIAID, NIH, USA). 
The HIV-2 strain ROD was obtained from the Medical Research Council 
(MRC, London, UK). The anti-HIV assay in MT-4 cells has been 
described previously.
29
 MT-4 cells (1x10
6 
cells/ml; 50 μl of volume) 
were pre-incubated for 30 min at 37°C with the test compounds in 96-
well plates (Falcon, BD Biosciences). The laboratory HIV strains 
(NL4.3 and ROD) were added according to the 50% tissue culture 
infectious dose (TCID50) of the viral stock. Cellular cytopathicity was 
scored microscopically in MT-4 cells 5 days post-infection and IC50s 
were calculated spectrophotometrically using MTS/PES. For the latter 
viability assay, the Cell-Titer96 Aqueous One Solution Proliferation 
Assay (Promega, Leiden, The Netherlands) kit was used. 
 
3.5.10 NMR analysis 
 
The NMR analysis of the peptides 25 and 39, was carried out in aqueous 
solution (1 mg peptide in 500 microliters H2O / D2O 9: 1 v / v pH 3.0) 
and in a 30% solution of TFE (1 mg peptide in 500 microliters to 30% 
TFE-d3 in H2O / D2O 9: 1 v / v pH 3.0), using DSS as reference. The 
NMR spectra were obtained by recording the measurements at 5 ° C and 







Chapter III: Design, synthesis, biological evaluation and conformational 
studies of peptides derived from N-terminal domain HIV-1 integrase 
81 
 
3.5.10.1 NMR assignment 
 
1
H chemical shifts were assigned by standard strategy based on 2D 
COSY, TOCSY and NOESY spectra. 
13





recorded at natural 
13
C abundance. 
In the case of peptide 39, which contains two Pro residues, only the 
major species was assigned. Based on the difference between the 
13
C 
chemical shifts for the Cβ and Cγ carbons (δCβ – δCγ, ppm; 3.3 and 4.6 
ppm for P5 & P6 in aqueous solution, and 3.5 and 4.2 ppm for P5 & P6 
in 30 % TFE), the two X-Pro bonds of the major species of 39 are trans 
(values for trans X-Pro bonds are < 5 ppm, and for cis X-Pro bonds are 
about 10 ppm).  
 
3.5.10.2 Structure calculations  
 
To visualise the structural features of the helices formed by peptides 25 
and 39 in the presence of TFE, we performed structure calculations. 
Upper limit distance restraints were derived from the NOE cross-peaks 
observed in 2D NOESY spectra recorded at 5ºC, and 25ºC. The 
automatic integration sub-routine of the Sparky program was employed 
to integrate the cross-peaks. Restraints for the ϕ and ψ dihedral angles 






Cβ chemical shifts using the 
TALOS-n server. Structures were calculated using the standard iterative 
protocol for automatic NOE assignment implemented in CYANA 2.1 
program. This protocol performs seven cycles of combined NOE 
assignment and structure calculation. 100 conformers were calculated 
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ensemble of the 20 conformers with the lowest target function values 
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Based on the preliminary screening data discussed in the third chapter, 
we focused on peptide 5 (EKYHSNWRAM), which showed a particular 
increases of the integrase activity in vitro assays (figure 4.1).
1
 Moreover, 
peptide 5 is included in the second NTD α-helix of integrase, known in 





Figure 4.1. Activity in vitro assay of peptide 5. 
 
In this section, we discuss the evaluation of  the activity of the peptide 5 
in cell, considering that the translocation through the plasma membrane 
is a major limiting step for the cellular delivery of macromolecules. A 
promising strategy to overcome this problem consists in the chemical 
conjugation (or fusion) to cell penetrating peptides (CPP) derived from 
proteins able to cross the plasma membrane.
3
 A large number of 
different cargo molecules such as oligonucleotides, peptides, peptide 
nucleic acids, proteins or even nanoparticles have been internalized in 
cells by this strategy.  
 
4.1 Cell penetrating peptides 
 
The integrity of cell membranes is critical to protect cells and for 
maintaining tissue homeostasis. Indeed the organization of cell 
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membranes prevents the leakage and the entrance of small molecules, 
proteins and genetic material in a not specific manner. The presence of 
cellular and tissue barriers is a strong drawback for drug delivery.  
Recently, a new and efficient strategy is based on the use of CPPs (cell-
penetrating peptides). The CPPs are peptides with a short sequence 
(fewer than thirty amino acids), able to cross the membrane at any point  
in a free manner. In this way, active molecules, antibodies, peptides, 
nanoparticles, nucleic acids, conjugated to a CPP, can be easily 




Therefore, the CPPs represent a revolutionary tool for the treatment of 
several human diseases, with a reduction of toxicity and invasiveness. 
The peptide TAT and Penetratine were the first CPPs discovered, and 
are still the most studied today.
5
 The HIV-1 TAT (transactivator of 
transcription) gene codes for a 14-kDa protein and as its name suggests, 
it is a key activator of HIV-1 transcription. It is one of the first proteins 
to be expressed after infection occurs. Unlike typical transcription 
factors that are DNA binding proteins, TAT is a RNA binding protein 
that recognizes a specific sequence, TAR (Transactivator Response 
Element), from the HIV-1 RNA molecule.
6
   
TAT is a protein which consists a transcriptional activation domain 
containing a  region enriched in cysteine and a hydrophobic motif 
enriched in arginine, that determines the binding of RNA protein. Park et 
al. defined the minimal peptide sequence (TAT 49-57) needed to cross 
membranes without losing efficiency. This region is enriched in basic 
aminoacids, lysine and arginine, and it is important for DNA binding. 
The peptides are relatively big molecules, so the transition from the 
external aqueous medium to the internal is difficult. Furthermore the  
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peptides, being of the amino acid polymers, have an electric charge, 
which does not allow the free passage through the cell membrane. 
Several studies show that the TAT peptide (GRKKRRQRRRPQ) can be 




4.1.1 Conjugation with fatty acids 
 
Another approach used to improve the pharmacokinetics properties is 
the conjugation of the peptide to a lipid. In this way, the half-life of the 
drug is prolonged, because it can remain more time in the circulation.  
Furthermore, the conjugated peptide to a lipid for various applications 
can be used, for example to increase their antibacterial activity.  
For the conjugation of a fatty acid to peptide various approaches are 
available. Usually the lipids are conjugated to the N-terminal sequence 
of the peptide, or to the side chain of lysine residue. Moreover the 
cysteine residues in a peptide sequence can be conjugated to fatty acids, 
giving the corresponding thioesters derivatives. Typically, the 
derivatization involves long-chain fatty acids. The commonly used fatty  
acids are caprylic acid (C8), lauric acid (C12), myristic acid (C14), 




4.2 Results  
 
4.2.1 Design of peptides able to penetrate in cells 
 
On the basis of the above considerations, in order to obtain compounds 
able to cross the cytoplasmic membrane, we conjugated peptide 5 with 
two vectors (Table 4.1): 
1. TAT sequence, GRKKRRQRRRPQ 
2. Palmitic Acid, a saturated fatty acid to 16 carbon atoms. 
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In this way the peptides could be able to cross the membrane and enter 
into the cell. 
 






4.2.2 Cell-based HIV replication assay on peptides 5, TAT-5 and PA-5 
 
The synthesized peptides were evaluated for their capability to inhibit 
the HIV-1 and HIV-2 replication in MT-4 cells infected with the virus 
(Table 4.2). Only peptide 5 conjugated with fragment TAT (TAT-5), 
showed a significant inhibitory activity against HIV-1 and  HIV-2 (IC50 
value in the low micromolar range).  
 
 
Table 4.2. Evaluation of the synthesized peptides against HIV-1 and HIV-2 
















5 5.02 1363.70 > 110 > 110 110± 0.6 
PA-5 5.67 1558.47 > 103 > 103 103± 0.2 
TAT-5 4.56 2924.37 27± 0.7 30± 0.3 113± 0.5 





a 50% Effective concentration, or compound concentration required to inhibit HIV-induced 
cytopathogenic effect in MT-4 cell culture. 
b Compound concentration required to reduce by 50% MT-4 cell viability. 
*GRKKRRQRRRPQ: TAT  
So, according to the results obtained, the contribution of the various 
amino acid residues to the antiviral activity of peptide TAT-5 was 
established through an L-Ala scanning analysis. 
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The compounds obtained, 47-55 were evaluated for their capacity to 
inhibit the replication of HIV-1 and HIV-2 in MT-4 cells infected with 
the virus. Unfortunately, the analysis of the data showed that neither of 
peptides inhibited the viral replication (Table 4.3). 
 
Table 4.3. Evaluation of the synthesized peptides (47-55) against HIV-1 and 
HIV-2 replication in MT-4 cell cultures. 
 
a 50% Effective concentration, or compound concentration required to inhibit HIV-induced 
cytopathogenic effect in MT-4 cell culture. 























TAT-5 TAT-EKYHSNWRAM 4.56 2924.37 27± 0.7 30± 0.3 113± 
0.5 TAT-47 TAT-AKYHSNWRAM 4.53 2866.34 > 10 > 10 > 50 
TAT-48 TAT-EAYHSNWRAM 3.45 2867.28 > 10 > 10 > 50 
TAT-49 TAT-EKAHSNWRAM 3.67 2832.27 > 10 > 10 > 50 
TAT-50 TAT-EKYASNWRAM 3.57 2858.31 > 10 > 10 > 50 
TAT-51 TAT-EKYHANWRAM 4.55 2908.37 > 10 > 10 > 50 
TAT-52 TAT-EKYHSAWRAM 3.24 2881.35 > 10 > 10 > 50 
TAT-53 TAT-EKYHSNARAM 4.42 2809.24 > 10 > 10 > 50 
TAT-54 TAT-EKYHSNWAAM 4.89 2839.26 > 10 > 10 > 50 
TAT-55 TAT-EKYHSNWRAA 3.79 2864.25 > 10 > 10 > 50 
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4.3 Chemistry  
 
4.3.1 General procedure for synthesis of PA-5 
 
The synthesis of peptide (PA-5) was performed according to the solid 
phase approach using standard Fmoc methodology in a manual reaction 
vessel.
9
 The first amino acid, was linked to the Rink resin previously 
deprotected by a 25% piperidine solution in N,N-dimethylformamide 
(DMF) for 30 min. The following protected amino acids were then 
added stepwise. Each coupling reaction was accomplished using an 
amino acid with HBTU and HOBt in the presence of DIPEA. The N-
terminal Fmoc group was removed with a 25% solution of piperidine in 
DMF, then the conjugation of palmitic acid was carried out.
10
 Finally, 
peptide were released from the resin with trifluoroacetic acid 
(TFA/TES/H2O (90:5:5) for 3 h. The resin was removed by filtration, 
and the crude peptides were recovered by precipitation with cold 
anhydrous ethyl ether to give a white powder and then lyophilized 
(figure 4.2).  
 
All crude peptides were purified by RP-HPLC on a preparative C18-
bonded silica column using a Shimadzu SPD 10A UV/VIS detector, 
with detection at 215 and 254 nm. All peptides were characterized with 
analytical RP-HPLC and peptides molecular weights were determined 
by ESI mass spectrometry in a MS Thermo Quest Finnigan LTQ 
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4.3.2 Synthesis of peptide TAT-5, TAT-47-55 
 
The synthesis of peptides conjugated to TAT fragment (TAT-5 and from 
TAT-47 to TAT-55) was carried out by microwave-assisted solid-phase 
synthesis,  on a Rink Amide-ChemMatrix.  
The advantages of the use of microwaves on chemical systems can be 
summarized as follows: (a) volumetric heating, without contact; (b) very 
high heating rate; (c) good interaction with many insulating materials 
and poor interaction with many nonferrous metals or gaseous products; 
and (d) convenient and clean heating system. The presence of 
microwaves greatly improves the rate of many chemical reactions, with 
a strong reduction of the reaction time, without altering the final yield. 
Reactions Chemistry by microwaves  can also be carried out in dry 
conditions or in solvents with a high dielectric constant.
11
 The synthesis 
by microwaves has found great success in organic chemistry, improving 
the yield and the completion of many reactions. The great success 
achieved in the organic field has also allowed the application in the 
chemistry of peptides (particularly the SPPS). Indeed, since the 
completion of a peptide synthesis requires the obtaining of two per cycle 
reactions (deprotection and coupling), the microwave energy is an 
efficient way to carry out these reactions. A frequent problem in peptide 
synthesis, in particular in long peptide sequences (30 or more amino 
acids) or hydrophobic is the aggregation of the chain. The energy 
derived by microwave is able to break the aggregation allowing the 
peptide to take on the favorable conformation at lower energy. Finally, 
the use of microwave can improve, in terms of yield and purity, the 
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During my PhD project a library of peptides was developed from the 
NTD sequence (1-50) by using a mimotopic strategy. Preliminary results 
of the in vitro integrase assay indicated that the peptide 5 
EKYHSNWRAM, increases significantly the HIV-1 IN activity. Peptide 
5 is included into the sequence of the 2
nd 
α-helix of NTD of integrase, 
which is known in the literature to be responsible of binding with the 
viral DNA. According to the antiviral activity in cell, the peptide 5 alone 
is not able to cross the cellular membrane, while PA-5 is not active in 
cell. We hypothesized that the presence of fatty acid makes the 
compound very slightly soluble, preventing the correct penetration of the 
peptide.  
Interestingly, peptide 5, conjugated with the cell-penetrating Tat 
fragment, is the only compound of this series able to inhibit the HIV-1 
and HIV-2 induced cytopathogenic effect in MT-4 cell. Although the 
antiviral activity is about 5-fold lower than the concentration of its 
cellular toxicity, peptide TAT-5 represents a suitable lead compound for 
the development of novel derivatives able to inhibit of the viral 
replication.  
Ala scanning performing on TAT-5 showed that all substitutions modify 
substantially the inhibitory activity of the resulting peptides. Similarly to 
what happened with first series, these data still showed the difficulty of 
establishing a structure-activity relationship with peptides that target the 
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4.5 Experimental section 
 




-Fmoc-protected amino acids, HOAt, HBTU, DIEA, piperidine and 
trifluoroacetic acid were purchased from Iris Biotech (Germany). Rink 
Amide-ChemMatrix resin was purchased from Biotage AB (Sweden). 
Palmitic Acid was purchased from Sigma-Aldrich. 
Peptide synthesis solvents, reagents, as well as CH3CN for HPLC were 
reagent grade and were acquired from commercial sources and used 
without further purification unless otherwise noted. 
 
4.5.1.1 Peptide synthesis by microwaves 
 
The peptides TAT-5 and from TAT-47 to TAT-55 were synthesized 
using a Biotage Syro Wave
TM
 fully automated microwave and parallel 
peptide synthesizer or assembled on the Automated Microwave Peptide 
Synthesizer from Biotage AB (Initiator+ Alstra™). 
Peptides were performed on a Rink Amide-ChemMatrix resin (150 mg, 
loading 0.4-0.6 mmol/g), previously deprotected with 25% 
piperidine/DMF (1x 3 min, 1x 10 min) at room temperature. The resin 
was then washed with DMF (4 x 4.5 ml).
 
The following protected amino 
acids were then added on to the resin stepwise. Coupling reactions were 
performed using N
α
-Fmoc amino acids (3.0 eq., 0.5 M), using as 
coupling reagent HBTU (3eq, 0.6M), HOAt (3eq, 0.5M) and DIEA (6eq,  
2M) in N-methyl-2-pyrrolidone (NMP). All couplings were achieved for 
10 min at 75 ºC (2x) and 2x45 min at RT for histidine and cysteine 
couplings to avoid the epimerization. After each coupling step, the Fmoc 
protecting group was removed as described above. 
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The resin was washed with DMF (4 × 4.5 ml) after each coupling and 
deprotection step. Finally peptides were released from the resin as 
described above. 
 
4.5.1.2 Synthetic Procedure: conjugation of the peptide with palmitic 
acid  
 
The synthesis of peptide PA-5 was performed according to the solid 




After deprotection of the Fmoc group, the conjugation of palmitic acid 
was carried out.
10
 So we used 4 equivalent of palmitic acid; 4.4 
equivalents of DIC (diisopropilcarbodiimide); 8 equivalent of HOBT; 
using DMF and DCM as the reaction solvent. These reagents were added 
under stirring keeping the reactor of the synthesis for 18 hours. Then, the 
peptides were washed several times with DCM (3x3 mL), DMF (2x3 
mL), again with DCM (2x3 mL) and finally with MeOH (2x3 mL). To 
confirm the reaction of addition of palmitic acid, the Kaiser test was 
carried out. 
At the end, we performed cleavage reaction using a mixture of 10 mL of 
90% TFA, 5% of Et3SiH (TES) and 5 % of H2O, stirring for 3 hours. 
Finally, the resin was removed from the solution by filtration and to the 
latter was added ethyl ether to give a white precipitate. The crude 
peptide was recovered through the use of a rotavapor, to obtain a white 
powder.  
 
4.5.2 Purification and characterization 
 
All crude peptides were purified by RP-HPLC on a preparative C18-
bonded silica column (Kinetex 5μm, 100Å, 100×21.2mm) using a 
Shimadzu SPD 10A UV−Vis detector, with detection at 210 nm and 254  
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nm. The column was perfused at a flow rate of 20 mL/min with solvent 
A (10%, v/v, water in 0.1% aqueous TFA), and a linear gradient from 
5% to 90% of solvent B (80%, v/v, acetonitrile in 0.1% aqueous TFA) 
over 20 min was adopted for peptide elution.  Analytical purity, was 
determined by RP-HPLC, using an autosampler, with dual wavelength 
absorbance detector with wavelength set to 215 nm, all of which were 
obtained from Shimadzu. The mobile phases employed were: solvent A 
(water + 0.1% TFA) and solvent B (acetonitrile + 0.1% TFA); using a 
linear gradient from 5% to 90% B over 11 min, fitted with C-18 column 
Phenomenex, Ascentis ES-C18 column (5cm х 3.0mm, 2.7µm), at a 
flow rate of 0.800 mL/min. ESI mass spectrometry was determined 
using a Q-Tof Premier (ESI/Q-Tof). The sample was dissolved in a 
mixture of water and methanol (50/50) and injected directly into the 
electrospray source, using a syringe pump, which maintains constant 
flow at 5 μL/min. The temperature of the capillary was set at 220 °C  
 
4.5.3 Cell-based assays 
 
The HIV-1 strain NL4.3 was obtained from the AIDS Research and 
Reference Reagent Program (Division of AIDS, NIAID, NIH, USA). 
The HIV-2 strain ROD was obtained from the Medical Research Council 
(MRC, London, UK). The anti-HIV assay in MT-4 cells has been 
described previously.
12
 MT-4 cells (1x10
6 
cells/ml; 50 μl of volume) 
were pre-incubated for 30 min at 37°C with the test compounds in 96-
well plates (Falcon, BD Biosciences). The laboratory HIV strains 
(NL4.3 and ROD) were added according to the 50% tissue culture 
infectious dose (TCID50) of the viral stock. Cellular cytopathicity was 
scored microscopically in MT-4 cells 5 days post-infection and IC50s 
were calculated spectrophotometrically using MTS/PES.  
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For the latter viability assay, the Cell-Titer96 Aqueous One Solution 
Proliferation Assay (Promega, Leiden, The Netherlands) kit was used. 
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The search for an effective therapy for the acquired immunodeficiency 
syndrome (AIDS) continues to be one of the biggest challenges for 
medicine. The success of highly active antiretroviral therapy (HAART) 
combinations, has improved patient long-term survival and tolerability 
to drug regimens. However, mutations of the HIV-1 genome confer 
resistance to those drugs in a large number of patients. Thus, the 
development of new inhibitors, targeting a distinct step in the retroviral 
life cycle, remains essential to reduce side effects and selection of drug-
resistant viruses. 
In this context, the viral enzyme integrase (IN), which is essential for the 
replication of human immunodeficiency virus type 1 (HIV-1), represents 
an important target for the development of new antiretroviral drugs. 
The structure of IN consists of three domains: the N-terminal domain, 
the core domain that has the catalytic DDE motif which is required for 
its enzymatic activity and the C-terminal domain. The design and 
discovery of integrase inhibitors were first focused at targeting the 
catalytic site of IN with a specific effect on strand transfer. However, 
mutations of the HIV-1 genome confer resistance to those drugs in a 
large number of patients. For this reason the aim of my PhD project was 
the identification of new allosteric modulators of HIV-1 integrase (IN). 
We focused on the N-terminal domain (NTD) of HIV-1 IN which plays 
an important role in the formation of tetramer integrase process. Indeed, 
this domain represents an important target for the design of drugs for 
inhibition of IN oligomerization process. Thus, we synthesized a library 
of overlapping peptide sequences, with specific length and specific 
offset covering the entire native protein sequence NTD IN 1-50 (1-15). 
Then, we focused on peptide 5 and peptide 11 included in the 2rd α-
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helix and the 3rd α-helix of N-terminal of IN respectively. Initially we 
synthesized three peptides derived from peptide 11, in which the Cys 
residue was deleted (peptide 16) or substituted by His amino acid a 
residue also involved in the Zn
2+
 coordination (peptide 17). The same 
His was also used to replace the C-terminal Ser residue of peptide 16 
leading to peptide 18.
 
We found that the most potent fragment, is peptide 
18 (VVAKEIVAH), which inhibits the HIV-1 IN activity with an IC50 
value of 4.5 µM. Amino acid substitution analysis on this peptide 
revealed essential residues for activity and allowed us to identify two 
nonapeptides (peptides 24 and 25), that show a potency of inhibition 
similar to the one of peptide 18.  
To verify whether active peptides 18, 24 and 25 can modulate the 
dynamic interplay between IN subunits, we tested them using an HTRF-
based IN subunit exchange assay. Interestingly, peptide 18 does not 
interfere with the dynamic interplay between IN subunits, while peptides 
24 and 25 modulated these interactions in different manners. Indeed, 
peptide 24 inhibited the IN-IN dimerization, while peptide 25 promoted 
IN multimerization, with IC50 values of 32 and 4.8 µM, respectively. In 
addition, peptide 25, conjugated with the cell-penetrating Tat, has shown 
to have selective anti-infective cell activity for HIV-1. These results 
indicate that peptide 25 represents a suitable lead compound for the 
development of novel derivatives with improved toxicity profile.  
To deepen on the structural requirements that determine the inhibitory 
activity of peptide 25 (VVAKAIVAH), we synthesized a new library 
containing the corresponding D-aminoacid (29-37, D-scanning  
analysis), while  to verify if the position/sequence of amino acids is 
important for activity, we also synthesized the peptide 25 scramble (38). 
In addition, we synthesized peptide 39 (DFNLPPVVAKAIVAH), 
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obtained from residues 25-39 of N-terminal sequence, which includes 
peptide 25 with addition of residues DFNLPP that may be essential to 
stabilize the conformation of the peptide.  
The results obtained from the analysis HTFR confirmed that peptide 25 
is the most powerful of the synthesized series. In addition to identify the 
shortest aminoacid sequence needed for the peptide activity we 
synthesized peptides 40-43 obtained from N- and C-terminal deletions of 
peptide 25. Subsequently, in order to improve pharmacokinetic 
properties of peptide 25, we design and synthesized cyclic peptides 
using different cyclization approaches  (peptides 44, 45 and 46); during 
the synthesis of peptide 44 we observed side reactions, solved with the 
use of Fmoc-His(Allyl)-Trityl resin, that has allowed to perform the 
cyclization reaction on the resin. So we obtained the desired cyclic 
peptide with a yield of 60%.  
The studies to evaluate the antiviral activity of trunks peptides and cyclic 
peptides are still in progress. While the thesis is waiting for completion 
of some biological results, it is expected that truncated and cyclic 
peptides could offer additional information to guide next steps in this 
subject. 
To evaluate the conformation of peptide 25 and peptide 39, a  NMR 
analysis was carried out. The NMR analysis showed an alpha helix 
conformation of peptide 25, which could be essential for the interaction 
with IN. 
Moreover, we considered to evaluate the activity of other peptides 
derived from the overlapping library of compounds, in particular we 
found that peptide 5 (EKYHSNWRAM), conveniently conjugated with 
the cell-penetrating fragment TAT, inhibits replication of HIV-1 and 
HIV-2 in infected MT-4 cells. Thus, contribution of the various amino  
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acid residues to the antiviral activity of peptide TAT-5 was established 
through an L-Ala scanning analysis peptide (47-55). Unfortunately, the 
analysis of the data showed that none of the synthesized peptides inhibit  
viral replication and all substitutions modify substantially the inhibitory 
activity of the resulting peptides. In conclusion, the results obtained in 
this PhD project confirmed peptide 25 (VVAKAIVAH) as the most 
powerful of the synthesized series and the NMR analysis showed an 
alpha-helix conformation, which might be essential for the interaction 
with IN; 
Moreover, we found that peptide 5 (EKYHSNWRAM), conveniently 
conjugated with the cell-penetrating fragment Tat, inhibits replication of 
HIV-1 and HIV-2 in infected MT-4 cells. 
These results encourage us to pursue the path for design and the 
development of peptides derived from the N-terminal domain of IN, as 
potential anti-HIV agents. 
 
